| Jun 3 |
Sanofi says Sarclisa improves progression-free survival in some multiple myeloma patients
|
| Jun 3 |
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
|
| Jun 3 |
3 Dividend Stocks to Buy in June 2024 for Dependable Dividend Growth
|
| Jun 3 |
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward
|
| Jun 3 |
GSK Plunges as Drugmaker Must Face Zantac Cases in Delaware
|
| May 31 |
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
|
| May 31 |
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
|
| May 31 |
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
|
| May 31 |
Regeneron/ Sanofi say FDA has delayed Dupixent COPD label
|
| May 31 |
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
|
